Adi Hoess, Affimed CEO
December 10, 2022 03:17 PM ESTUpdated December 12, 10:27 AM
R&D

#ASH22: 'Not so sur­pris­ing': With lack of dura­bil­i­ty, Af­fimed scraps monother­a­py plans in fa­vor of NK cell com­bo

Kyle LaHucik

Senior Reporter

NEW OR­LEANS — Af­fimed won’t move ahead with an ac­cel­er­at­ed ap­proval ap­pli­ca­tion for its drug AFM13, an in­nate cell en­gager it was test­ing in re­lapsed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times